Adding heart rate signal to a control-to-range artificial pancreas system improves the protection against hypoglycemia during exercise in type 1 diabetes.
BACKGROUND
We present a clinical trial establishing the feasibility of a control-to-range (CTR) closed-loop system informed by heart rate (HR) and assess the effect of HR information added to CTR on the risk for hypoglycemia during and after exercise.


METHODS
Twelve subjects with type 1 diabetes (five men, seven women; weight, 68.9 ± 3.1 kg; age, 38 ± 3.3 years; glycated hemoglobin, 6.9 ± 0.2%) participated in a randomized crossover clinical trial comparing CTR versus CTR+HR in two 26-h admissions, each including 30 min of mild exercise. The CTR algorithm was implemented in the DiAs portable artificial pancreas platform based on an Android(®) (Google, Mountainview, CA) smartphone. We assessed blood glucose (BG) decline during exercise, the Low BG Index (LBGI) (a measure of hypoglycemic risk), number of hypoglycemic episodes (BG <70 mg/dL) and overall glucose control (percentage time within the target range 70 mg/dL ≤ BG ≤ 180 mg/dL).


RESULTS
Using HR to inform the CTR algorithm reduced significantly the BG decline during exercise (P=0.022), indicated marginally lower LBGI (P=0.3) and fewer hypoglycemic events during exercise (none vs. two events; P=0.16), and resulted in overall higher percentage time within the target range (81% vs. 75%; P=0.2). LBGI and average BG remained unchanged overall, during recovery, and overnight.


CONCLUSIONS
HR-informed closed-loop control can be implemented in a portable artificial pancreas. Although closed loop has been shown to reduce hypoglycemia, adding HR signal may further limit the risk for hypoglycemia during and immediately after exercise. The most prominent effect of adding HR information is reduced BG decline during exercise, without deterioration of overall glycemic control.
Center for Diabetes Technology, University of Virginia , Charlottesville, Virginia.
Marc D
MD
Breton
Sue A
SA
Brown
Colleen Hughes
CH
Karvetski
Laura
L
Kollar
Katarina A
KA
Topchyan
Stacey M
SM
Anderson
Boris P
BP
Kovatchev
D000328:Adult; D000465:Algorithms; D001786:Blood Glucose / Q000187:drug effects; D018592:Cross-Over Studies; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D015444:Exercise; D005240:Feasibility Studies; D005260:Female; D006442:Glycated Hemoglobin / Q000187:drug effects* / Q000378:metabolism; D006339:Heart Rate; D006801:Humans; D007003:Hypoglycemia / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008991:Monitoring, Physiologic; D019397:Pancreas, Artificial / Q000009:adverse effects; D010865:Pilot Projects; D016896:Treatment Outcome
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human